533 related articles for article (PubMed ID: 11457586)
1. Drastic neuronal loss in vivo by beta-amyloid racemized at Ser(26) residue: conversion of non-toxic [D-Ser(26)]beta-amyloid 1-40 to toxic and proteinase-resistant fragments.
Kaneko I; Morimoto K; Kubo T
Neuroscience; 2001; 104(4):1003-11. PubMed ID: 11457586
[TBL] [Abstract][Full Text] [Related]
2. In vivo conversion of racemized beta-amyloid ([D-Ser 26]A beta 1-40) to truncated and toxic fragments ([D-Ser 26]A beta 25-35/40) and fragment presence in the brains of Alzheimer's patients.
Kubo T; Nishimura S; Kumagae Y; Kaneko I
J Neurosci Res; 2002 Nov; 70(3):474-83. PubMed ID: 12391608
[TBL] [Abstract][Full Text] [Related]
3. Co-injection of beta-amyloid with ibotenic acid induces synergistic loss of rat hippocampal neurons.
Morimoto K; Yoshimi K; Tonohiro T; Yamada N; Oda T; Kaneko I
Neuroscience; 1998 May; 84(2):479-87. PubMed ID: 9539218
[TBL] [Abstract][Full Text] [Related]
4. [Neurotoxicity of beta-amyloid].
Kaneko I; Kubo T; Morimoto K
Nihon Yakurigaku Zasshi; 2000 Feb; 115(2):67-77. PubMed ID: 10876793
[TBL] [Abstract][Full Text] [Related]
5. Beta-amyloid racemized at the Ser26 residue in the brains of patients with Alzheimer disease: implications in the pathogenesis of Alzheimer disease.
Kubo T; Kumagae Y; Miller CA; Kaneko I
J Neuropathol Exp Neurol; 2003 Mar; 62(3):248-59. PubMed ID: 12638729
[TBL] [Abstract][Full Text] [Related]
6. [Amyloidogenic peptides such as beta-amyloid, amylin and calcitonin strongly enhance the susceptibility of rat hippocampal neurons to excitatory amino acids in vivo].
Morimoto K; Nagata S; Kubo T; Oda T; Kaneko I
Nihon Yakurigaku Zasshi; 1998 Oct; 112 Suppl 1():83P-87P. PubMed ID: 10190140
[TBL] [Abstract][Full Text] [Related]
7. Racemization: its biological significance on neuropathogenesis of Alzheimer's disease.
Mori H; Ishii K; Tomiyama T; Furiya Y; Sahara N; Asano S; Endo N; Shirasawa T; Takio K
Tohoku J Exp Med; 1994 Nov; 174(3):251-62. PubMed ID: 7761990
[TBL] [Abstract][Full Text] [Related]
8. Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative racemized at Ser residue.
Kaneko I; Yamada N; Sakuraba Y; Kamenosono M; Tutumi S
J Neurochem; 1995 Dec; 65(6):2585-93. PubMed ID: 7595555
[TBL] [Abstract][Full Text] [Related]
9. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease.
Nagele RG; D'Andrea MR; Anderson WJ; Wang HY
Neuroscience; 2002; 110(2):199-211. PubMed ID: 11958863
[TBL] [Abstract][Full Text] [Related]
10. Additive toxicity of β-amyloid by a novel bioactive peptide in vitro: possible implications for Alzheimer's disease.
Garcia-Ratés S; Lewis M; Worrall R; Greenfield S
PLoS One; 2013; 8(2):e54864. PubMed ID: 23390503
[TBL] [Abstract][Full Text] [Related]
11. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
Cottingham MG; Hollinshead MS; Vaux DJ
Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease: Mental plaque removal.
De Strooper B; Woodgett J
Nature; 2003 May; 423(6938):392-3. PubMed ID: 12761533
[No Abstract] [Full Text] [Related]
13. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease.
Kumar-Singh S; De Jonghe C; Cruts M; Kleinert R; Wang R; Mercken M; De Strooper B; Vanderstichele H; Löfgren A; Vanderhoeven I; Backhovens H; Vanmechelen E; Kroisel PM; Van Broeckhoven C
Hum Mol Genet; 2000 Nov; 9(18):2589-98. PubMed ID: 11063718
[TBL] [Abstract][Full Text] [Related]
14. Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues.
Tomiyama T; Asano S; Furiya Y; Shirasawa T; Endo N; Mori H
J Biol Chem; 1994 Apr; 269(14):10205-8. PubMed ID: 8144598
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).
Miguel-Hidalgo JJ; Alvarez XA; Cacabelos R; Quack G
Brain Res; 2002 Dec; 958(1):210-21. PubMed ID: 12468047
[TBL] [Abstract][Full Text] [Related]
16. Fibrillar amyloid-beta affects neurofibrillary changes but only in neurons already involved in neurofibrillary degeneration.
Wegiel J; Bobinski M; Tarnawski M; Dziewiatkowski J; Popovitch E; Miller DC; Wisniewski T; Golomb J; de Leon MJ; Reisberg B
Acta Neuropathol; 2001 Jun; 101(6):585-90. PubMed ID: 11515787
[TBL] [Abstract][Full Text] [Related]
17. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome.
Gyure KA; Durham R; Stewart WF; Smialek JE; Troncoso JC
Arch Pathol Lab Med; 2001 Apr; 125(4):489-92. PubMed ID: 11260621
[TBL] [Abstract][Full Text] [Related]
18. The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide.
Boland K; Behrens M; Choi D; Manias K; Perlmutter DH
J Biol Chem; 1996 Jul; 271(30):18032-44. PubMed ID: 8663372
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease and amyloid: culprit or coincidence?
Skaper SD
Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
[TBL] [Abstract][Full Text] [Related]
20. Alpha2-macroglobulin attenuates beta-amyloid peptide 1-40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons.
Du Y; Bales KR; Dodel RC; Liu X; Glinn MA; Horn JW; Little SP; Paul SM
J Neurochem; 1998 Mar; 70(3):1182-8. PubMed ID: 9489740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
